Resistance to enfuvirtide, the first HIV fusion inhibitor.
about
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral TherapyCurrent perspectives on HIV-1 antiretroviral drug resistanceAutomated solid-phase peptide synthesis to obtain therapeutic peptidesSynergizing vaccinations with therapeutics for measles eradicationA virocidal amphipathic -helical peptide that inhibits hepatitis C virus infection in vitroDesign of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potencyShort-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptideThe M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsStructural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32MValidation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretroviralsTreatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesMolecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanismIdentification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitorOrigins of resistance to the HIVgp41 viral entry inhibitor T20.Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potencyCharacterization of HCV genotype 5a envelope proteins: implications for vaccine development and therapeutic entry target.Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rγ(-/-) (NSG) BLT mice.HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketHendra and nipah infection: pathology, models and potential therapies.Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release.A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathwaysFootprint-based identification of viral entry inhibitors targeting HIVgp41.Enfuvirtide: the first HIV fusion inhibitor.Emerging anti-HIV drugs.Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Achievements and challenges in antiviral drug discovery.A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in VitroA suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity
P2860
Q24534620-948D1E09-7BAC-4301-BB8E-6C7F5B0F8DCBQ26750980-120C0859-6A9D-4F28-8416-64705EFB4AECQ26852626-1515FB90-F5F0-49DE-BB78-CA265E210315Q27001623-A01D773F-65CD-4E54-A07F-023DA0DFB8EAQ27003149-EA150746-B972-4F12-A2F8-335F80C0C60EQ27485575-97C1373A-13DD-4B7B-B533-65112E0F9B35Q27650133-562433F1-FBD9-4284-8EFA-706F721A1DF4Q27666404-3755E71F-E880-4DE8-879C-8563413DAB2BQ27671434-0B5011C1-6B10-4417-A4B2-3B3486CC5C99Q27679547-152E9C01-38A9-4594-845B-E148041603B9Q28469262-A0192E89-6858-4FDC-8183-F6FB567CE325Q28476227-81BC96BE-EC23-4771-8981-ADDFDCD110C8Q28478943-2D770C36-E12D-4EAD-813C-BED7F9E06725Q28544927-DF481D89-E420-4B3A-895B-C38B22A4720FQ33622229-18DBB712-95D5-406B-A6C8-09181B4118A2Q33713101-5D7EA36A-A8B4-4F3E-A66C-6327C740CF7BQ33780643-D4B88BA1-6BF4-44D8-B889-ECAB6B3EDA65Q33840121-D15D34CE-F3F4-46A2-B738-46751416EAE6Q34108713-B1DA4626-C470-4B68-AE09-3C508149FB0AQ34310045-68C35E9A-B190-4E93-9119-5027CD63591EQ34800822-054642E0-B2E1-4890-86B9-1277DE27183DQ34864567-2AFE0B93-80E3-4471-9A68-3AE812D692D4Q35154146-CAD5E76F-C962-45C8-A7EB-7467460F1F83Q35542610-B036507E-0EA6-44ED-85DB-5469AB1BD8B1Q35599288-A55B977D-4A77-488F-AEF6-750184FD4E0CQ35641194-1B554AAE-C875-40D9-B99E-64099D92A9FAQ35658146-22CBF46A-B49D-4FA2-A46F-792CE369C132Q35666063-E626AEEF-10B0-4DFB-BE59-549960B1EF36Q35666270-88D8C833-67E3-4C63-B2EA-86A6A18A07A8Q35857279-562A69D3-DE83-4EB6-AB7E-B76F00235CF9Q35868288-17E34045-6B4B-4F62-8C24-EAE69D49443AQ35874697-781ECC3C-D020-49A0-90D9-CBB170A4CB65Q36082073-30AECC04-C46B-42F3-B237-A7E3B0A055DDQ36150601-4DC641FB-CA3E-4B1B-BAEE-EA8DEEBE188CQ36175788-480DF1A5-264D-4730-8AA3-5B0FBB740E93Q36186792-74122FF2-8DDC-468B-AC94-3E74D8096CB7Q36281607-0776A7E6-0972-4843-94D6-8BE5C8A9B29AQ36297991-F9E66CD4-BB5E-4C73-A057-79D0DD802D37Q36334376-3BF3FBFA-C424-4BB0-B097-D99A9591C508Q36558535-F6E4546D-AAAB-43D5-918E-F36C6862EED4
P2860
Resistance to enfuvirtide, the first HIV fusion inhibitor.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@ast
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@en
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@nl
type
label
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@ast
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@en
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@nl
prefLabel
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@ast
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@en
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@nl
P356
P1476
Resistance to enfuvirtide, the first HIV fusion inhibitor.
@en
P2093
Michael L Greenberg
Nick Cammack
P304
P356
10.1093/JAC/DKH330
P407
P577
2004-07-01T00:00:00Z